The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Applications of ctDNA in lung cancer: informing treatment approaches, MRD and screening
Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, reflects on the use of circulating tumor DNA (ctDNA) approaches in lung cancer, initially to identify targetable mutations for which there are treatment approaches, and now for minimal disease monitoring (MRD), screening and identifying mechanisms of resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
